Observational studyESC heart failure2026
Interplay between acute heart failure and COPD in patients hospitalized for dysponea: prognostic insights from the PARADISE cohort.
Observational study in ESC heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interpreting prognostic asymmetry in heart failure-chronic obstructive pulmonary disease overlap.ESC heart failure · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionHeart failure (HF) and chronic obstructive pulmonary disease (COPD) are leading causes of acute dyspnoea in the emergency department (ED) and frequently coexist. However, their combined impact on short- and long-term outcomes in the acute setting remains insufficiently characterized.
methodsWe conducted a monocentric observational study based on the PARADISE cohort, including patients admitted to the ED for acute dyspnoea between 2010 and 2019. Patients with a primary diagnosis of HF or COPD were included and stratified according to the presence of the alternate condition. The primary outcomes were in-hospital and post-discharge all-cause mortality, assessed using multivariable regression models.
resultsAmong 5131 patients, 3543 had a primary diagnosis of HF and 1588 of COPD. Concomitant disease was present in approximately 20% of patients in both groups.In the primary HF cohort, patients with COPD had lower in-hospital mortality compared with those without COPD (8.5% vs. 11.7%, P = .014), but similar overall mortality (69.3% vs. 68.9%). After adjustment, COPD remained associated with lower in-hospital mortality (OR 0.74; 95% CI 0.55-0.99; P = .050) and with a modest increase in long-term mortality (HR 1.22; 95% CI 1.09-1.36; P < .001).In the primary COPD cohort, patients with HF had higher in-hospital mortality (7.4% vs. 3.4%, P = .001) and markedly higher long-term mortality (68.7% vs. 48.7%, P < .001). After adjustment, HF was not significantly associated with in-hospital mortality (OR 1.54; 95% CI 0.87-2.65; P = .13), but remained strongly associated with increased long-term mortality (HR 1.48; 95% CI 1.25-1.76; P < .001).
conclusionHF and COPD frequently coexist and are both associated with an increased long-term mortality risk, with a greater prognostic impact of HF in patients with COPD. These findings highlight the importance of systematic identification and optimized management of both conditions in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.